Saturday, February 8, 2025

CATEGORY

Boehringer Ingelheim

Boehringer Shares Phase III Schizophrenia Trial Results

Key TakeawaysBoehringer Ingelheim reports Phase III iclepertin trial did not meet primary endpoints. No significant cognitive improvements observed in schizophrenia patients over six...

Boehringer Ingelheim Expands Oncology Portfolio with Synaffix ADC Technology

Key TakeawaysBoehringer Ingelheim licenses Synaffix’s ADC technology to enhance its oncology pipeline. The partnership includes a potential milestone value of $1.3 billion. The...

Boehringer Ingelheim and Sutro Biopharma Scale Up Cell-Free ADC Manufacturing

Key TakeawaysBoehringer Ingelheim and Sutro Biopharma achieved a breakthrough in cell-free manufacturing of antibody-drug conjugates (ADCs) at a commercial scale. Luveltamab tazevibulin (luvelta),...

Boehringer Ingelheim Fights Rabies in Kenya Through Vaccines

Key TakeawaysBoehringer Ingelheim and VSF Germany partner to combat rabies in Kenya. Vaccination campaigns, education, and community awareness aim to reduce rabies cases. ...

G-BA Restricts Coverage for In Vitro Stem Cell Preparation in Acute Leukemia Treatment

Key TakeawaysG-BA limits statutory health insurance (GKV) coverage for in vitro stem cell preparation in adults with acute leukemia. Coverage applies only in...

Boehringer Ingelheim Introduces VETMEDIN® Solution: A New Option for Canine Heart Disease

Key TakeawaysBoehringer Ingelheim launches VETMEDIN® Solution, the first FDA-approved oral liquid for congestive heart failure in dogs. This innovative solution addresses heart disease...

Boehringer Ingelheim Advances in Health Equity with ATMI Success

Key TakeawaysBoehringer Ingelheim ranked 8th in the 2024 Access to Medicine Index, advancing from 13th in 2022. This leap reflects the company’s strategic...

Raising Awareness on Type 2 Diabetes with ‘Blue Table’

Key TakeawaysBoehringer Ingelheim and TEMD launch the ‘Diabetes Blue Table’ initiative. The program highlights lifestyle changes to prevent and manage Type 2 diabetes. ...

Boehringer Ingelheim and Broad Institute Collaborate on Mental Health Treatment Innovations

Key TakeawaysBoehringer Ingelheim partners with the Broad Institute to target cognitive impairment in mental health conditions. The focus is on innovative treatments that...

TEMD Launches “Diabetes Blue Table” to Raise Awareness

Key TakeawaysThe "Diabetes Blue Table" project highlights Type 2 diabetes prevention and management through lifestyle changes. Experts from TEMD, alongside public figures, discuss...

Boehringer Ingelheim and Circle Pharma Partner to Develop Novel Cancer Therapy Targeting Cyclins

Key TakeawaysBoehringer Ingelheim and Circle Pharma collaborate to develop a first-in-class cyclin inhibitor for treating hard-to-treat cancers. Circle Pharma’s macrocycle platform offers a...

Boehringer Ingelheim’s Survodutide Receives FDA Breakthrough Therapy Designation, Initiates Phase III Trials for MASH

Key TakeawaysThe U.S. FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s survodutide for treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or...

Boehringer Ingelheim Partners with NCD Alliance to Improve Care for Non-Communicable Diseases

Key TakeawaysBoehringer Ingelheim partners with NCD Alliance to address global inequities in non-communicable disease (NCD) care, particularly in underserved communities. The partnership will...

Study Meets Primary Endpoint in Pivotal Phase-III Trial for IPF Treatment

Key TakeawaysNerandomilast significantly improved lung function, measured by Forced Vital Capacity (FVC) in patients with IPF over 52 weeks, compared to placebo. Boehringer...

Lung Cancer Patients with HER2 Mutations Show Promising Response to Boehringer’s Zongertinib in Phase Ib Trial

Key TakeawaysZongertinib demonstrated a confirmed objective response rate (ORR) of 66.7% in patients with HER2-mutated non-small cell lung cancer (NSCLC), with 94% of...

Latest news